Literature DB >> 31060039

Challenging the Current Risk Factors of Appendiceal Neuroendocrine Neoplasms: Can They Accurately Predict Local Lymph Nodal Invasion? Results from a Large Case Series.

Michail Galanopoulos1, Rory McFadyen2, Ioanna Drami3, Rishi Naik2, Nicholas Evans2, Tu Vinh Luong4, Jennifer Watkins4, Martyn Caplin1, Christos Toumpanakis5.   

Abstract

BACKGROUND: Appendiceal neuroendocrine neoplasms (ANEN) are uncommon entities, which run mostly an indolent course. Appendicectomy alone is usually curative, except for in a selected group of patients that are deemed to be at risk of loco-regional metastases, in whom a completion right hemicolectomy (RHC) is recommended. The current "Guidelines" criteria for the latter have been controversial, and may result in overtreatment, which is concerning for a young patient population.
OBJECTIVE: The aim of this study is to evaluate the prognostic value of the current criteria in identifying more accurately those at-risk patients.
METHODS: This was a retrospective study of the 263 cases of ANEN referred for advice or management to a tertiary referral unit over a 10-year period. Seventy-two patients underwent RHC, based on criteria, suggested by International Guidelines. Each one of those was assessed to identify whether it correlated with lymph node invasion (LNI) at the RHC surgical specimen.
RESULTS: Tumour grade (p < 0.001), vascular (p = 0.044) and lymph vessel invasion (p < 0.001) were all found to be statistically significant independent risk factors for LNI identified following RHC, whilst tumour size (p = 0.375) and mesoappendiceal invasion (MAI) (p = 0.317) were not statistically significant. However, deep MAI and tumour size >2 cm showed a correlation with each other on LNI positive subgroup analysis. Location in appendiceal base made LNI more likely but again was not significant (p = 0.133).
CONCLUSIONS: Higher tumour grade and lymphovascular invasion should be considered as the most important risk prognosticators. Surprisingly, tumour size was not found to be significant in our cohort. Further international multicentre studies with large numbers of patients are needed to fully validate those data.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Appendiceal neuroendocrine neoplasms; Appendicectomy; Appendix; Carcinoid; Lymph node invasion; Neuroendocrine tumours; Right hemicolectomy

Mesh:

Year:  2019        PMID: 31060039     DOI: 10.1159/000499381

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  4 in total

Review 1.  Management of incidentally discovered appendiceal neuroendocrine tumors after an appendicectomy.

Authors:  José Luis Muñoz de Nova; Jorge Hernando; Miguel Sampedro Núñez; Greissy Tibisay Vázquez Benítez; Eva María Triviño Ibáñez; María Isabel Del Olmo García; Jorge Barriuso; Jaume Capdevila; Elena Martín-Pérez
Journal:  World J Gastroenterol       Date:  2022-04-07       Impact factor: 5.374

Review 2.  Neuroendocrine neoplasms of the appendix, colon and rectum.

Authors:  Marco Volante; Federica Grillo; Federica Massa; Francesca Maletta; Luca Mastracci; Michela Campora; Jacopo Ferro; Alessandro Vanoli; Mauro Papotti
Journal:  Pathologica       Date:  2021-02

3.  The effect of prophylactic surgery in survival and HRQoL in appendiceal NEN.

Authors:  Krystallenia I Alexandraki; Gregory Kaltsas; Simona Grozinsky-Glasberg; Kira Oleinikov; Beata Kos-Kudła; Angelika Kogut; Rajaventhan Srirajaskanthan; Michail Pizanias; Kalliopi-Anna Poulia; Clara Ferreira; Martin O Weickert; Kosmas Daskalakis
Journal:  Endocrine       Date:  2020-07-24       Impact factor: 3.633

4.  The risk of lymph node metastases and their impact on survival in patients with appendiceal neuroendocrine neoplasms: a systematic review and meta-analysis of adult and paediatric patients.

Authors:  Kosmas Daskalakis; Krystallenia Alexandraki; Evanthia Kassi; Marina Tsoli; Anna Angelousi; Athanasia Ragkousi; Gregory Kaltsas
Journal:  Endocrine       Date:  2019-09-06       Impact factor: 3.633

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.